Core Viewpoint - The company aims to become a global leader in the high-end nutrition and health industry, demonstrating strong growth across its three core business units and maintaining healthy profitability and cash flow [2][30]. Group 1: Financial Performance - In 2025, the company reported a revenue of 14.35 billion RMB, a year-on-year increase of 10.3%. The adjusted EBITDA margin was 14.3%, and the adjusted net profit margin was 4.6%, reflecting a 22.7% increase year-on-year [2]. - The revenue from the Chinese market reached 10.20 billion RMB, growing by 17.5% and contributing 71.1% to the total revenue [2]. Group 2: Adult Nutrition and Care (ANC) Business - The ANC business generated revenue of 6.95 billion RMB, a 4.4% increase, accounting for 48.4% of total revenue. Swisse achieved a 13.3% growth in the Chinese market, representing 70.7% of ANC sales [6]. - Swisse reached a milestone of 1 billion USD in global revenue in 2025 and maintained its No.1 position in the vitamin, herbal, and mineral supplements market in mainland China [2][5]. Group 3: Infant Nutrition and Care (BNC) Business - The BNC business reported revenue of 5.26 billion RMB, a 20% increase, making up 36.6% of total revenue. The sales of infant formula in mainland China grew by 28.3%, significantly outpacing the overall market growth [15][31]. - The market share of the ultra-premium infant formula brand reached a historical high of 17.1% [3]. Group 4: Pet Nutrition and Care (PNC) Business - The PNC business achieved revenue of 2.15 billion RMB, an 8.7% increase, contributing 15.0% to total revenue. High-end pet nutrition products saw a 14.3% growth [4][24]. - In North America, the Zesty Paws brand maintained a strong growth rate of 12.8%, while the overall PNC business in North America grew by 7.5% [26]. Group 5: Strategic Initiatives and Future Outlook - The company is focused on optimizing its capital structure, reducing the net leverage ratio from 3.99 times in 2024 to 3.45 times in 2025, while maintaining a cash reserve of over 1.7 billion RMB [4][30]. - The company plans to continue driving growth through high-quality innovation, expanding its product offerings in the nutrition and infant formula sectors, and enhancing its market presence in both domestic and international markets [30][32].

Core Viewpoint - H&H International Holdings reported a total revenue of 7.019 billion yuan for H1 2025, reflecting a 5% year-on-year increase, with adjusted comparable EBITDA of 1.101 billion yuan, down 3% year-on-year, and adjusted comparable net profit of 363 million yuan, up 5% year-on-year. The company is expected to see EPS of 0.79, 1.05, and 1.30 yuan for 2025-2027, with a "Buy" investment rating assigned by Huaxin Securities [1]. Revenue and Profitability - The company achieved a gross margin increase of 2 percentage points to 62.53% in H1 2025, driven by improved margins in adult and pet nutrition and care products, along with product mix optimization [1]. - The proportion of sales and distribution/administrative expenses to revenue increased by 3 percentage points and decreased by 0.4 percentage points to 42.33% and 5.68%, respectively, due to changes in the channel mix for adult nutrition and care products in mainland China and investments in new market expansion strategies [1]. - Adjusted comparable EBITDA margin and adjusted comparable net profit margin decreased by 1 percentage point and 0.02 percentage points to 15.68% and 5.17%, respectively, primarily due to high base effects from the previous year and increased selling expenses [1]. Business Segment Performance - In H1 2025, revenue from adult nutrition and care products increased by 5% to 3.439 billion yuan, largely due to the outstanding performance of Swisse's innovative anti-aging product line, which saw a 39% growth compared to the benchmark [2]. - Revenue from infant nutrition and care products rose by 3% to 2.501 billion yuan, supported by effective e-commerce channel development and educational initiatives for new mothers in specialty stores, with the product successfully transitioning to new national standards [2]. - Revenue from pet nutrition and care products increased by 10% to 1.079 billion yuan, with gross margin rising by 12 percentage points to 58.70%, driven by deepened North American channel cooperation and the ongoing high-end upgrade of Solid Gold in mainland China [2]. Regional and Channel Insights - Revenue from mainland China in H1 2025 grew by 9% to 4.936 billion yuan, primarily due to strong growth in adult nutrition and care products and rapid channel expansion, with cross-border e-commerce revenue increasing by 18% and Douyin channel revenue surging by 80% [3]. - Revenue from Australia and New Zealand decreased by 18% to 801 million yuan, mainly due to a decline in corporate purchasing business [3]. - North American revenue increased by 6% to 862 million yuan, benefiting from the popularity of high-end pet nutrition products and the growing pet population, with major retailers like Amazon and Walmart performing well [3]. - Other regions saw a revenue increase of 17% to 420 million yuan, with strong growth in the Asian expansion market [3].

Core Insights - The core viewpoint of the article highlights the financial performance of Jianhe Group in the first half of 2025, showcasing a revenue growth of 5.2% year-on-year to 7.02 billion yuan [1] Revenue Performance - The total revenue for Jianhe Group reached 7.02 billion yuan, with a year-on-year increase of 5.2% [1] - The Chinese market contributed the most to the revenue, with an increase of 8.7%, accounting for 70.3% of total revenue [1] Business Segment Analysis - Among the three major business segments, the pet nutrition and care products segment experienced the highest revenue growth [1] - The adult nutrition and care products segment had the largest revenue share, amounting to 3.44 billion yuan [1] - For the infant nutrition and care segment, Jianhe Group anticipates steady growth in sales of infant formula in the second half of the year [1]